Table 3.

Associations between time-varying statin and NSAID use and the risk of esophageal adenocarcinoma

MedicationPersonsCasesUnadjusted HR (95% CI)Age & sex-adjusted HR (95% CI)Model 1c HR (95% CI)Model 2 HR (95% CI)
All study population39545
 Statin143a110.71 (0.32–1.61)0.63 (0.28–1.42)0.59 (0.26–1.33)0.68 (0.30–1.54)d
 NSAID284b230.68 (0.38–1.23)0.57 (0.32–1.01)0.58 (0.32–1.02)0.62 (0.34–1.10)e
HGD at baseline6930
 Statin25a60.44 (0.16–1.20)0.35 (0.12–1.07)0.31 (0.11–0.86)0.41 (0.13–1.26)d
 NSAID43b120.44 (0.20–0.96)0.36 (0.16–0.80)0.37 (0.17–0.83)0.46 (0.19–1.09)e
  • aEver used statins at baseline or over follow-up.

  • bEver used NSAIDs at baseline or over follow-up.

  • cAdjusted sex, age (continuous linear), and pack-years smoked (continuous linear).

  • dAdjusted sex, age (continuous linear), pack-years smoked (continuous linear), and use of NSAIDs (yes/no) over follow-up.

  • eAdjusted sex, age (continuous linear), pack-years smoked (continuous linear), and use of statins (yes/no) over follow-up.